The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP

Biotech ETFs are highlighted as a momentum opportunity as the NYSE Arca Biotechnology Index and Nasdaq Biotechnology Index are up ~30% YTD, versus the Nasdaq 100’s ~17%. Amgen shares are up 35.2% YTD after plans to invest an additional $300M in U.S. manufacturing capacity, while Crinetics (CRNX) rose 82% YTD on PALSONIFY uptake and Halozyme (HALO) gained 59.9% YTD with 48% YoY revenue growth in Q2 2026 driven by ENHANZE partner sales. The article also cites a 15% increase in Goldman Sachs’ 2030 obesity-drug sales forecast to $114B and points to ETF examples including FBT (+31.6% YTD, 55 bps fees), BBH (+29% YTD, 35 bps), and BBP (+37.5% YTD, 34 bps).

Analysis

The tradable implication is a rotation from story biotech into revenue-backed biotech. If flows continue, the winners are the liquid, index-heavy names that can absorb passive demand and support more debt/fundamental resilience; that favors AMGN and HALO over smaller, single-asset names where every trial date still dominates valuation. The second-order effect is that ETF ownership can become a bid for acquisition candidates, lifting midcap takeout floors and compressing the dispersion that active managers rely on.

The key risk is duration. Biotech multiples remain highly sensitive to real yields and risk appetite, so a 25-50 bp backup in long rates can offset several quarters of product/newsflow gains, especially for non-cash-flowing names. Near term, the market may already be crowded into the year-to-date winners, so the first failure mode is not fundamentals but a stall in relative strength versus the Nasdaq 100 and XBI-style breadth.

Contrarian view: the consensus is treating innovation as a sector-wide beta story, but the real alpha is likely narrower. The market is probably overpaying for "biotech as a theme" while underpricing how much of the upside is concentrated in a handful of approved, monetizing franchises; if M&A slows or upcoming clinical reads disappoint, the ETF complex can mean-revert quickly even if the best operators hold up. Falsifier: sustained underperformance of biotech ETFs versus NDX over the next 4-8 weeks, or a clear upside surprise in rates that expands discount rates and hits high-duration names.

Key Decisions for Investors

• Long BBH vs. short XBI for 1-3 months: own large-cap, cash-generative biotech and fade the most binary parts of the complex; thesis breaks if equal-weight biotech breadth keeps outperforming on two successive clinical/M&A catalysts.
• Accumulate FBT on pullbacks over the next 2-4 weeks rather than chase strength: it offers broader diversification than single-name exposure, with better downside containment if one pivotal readout goes wrong.
• Keep HALO on a buy list into any sector shakeout: the asymmetry is better than the average biotech because commercialization/partner economics are easier to underwrite than pipeline-only stories; trim if the stock loses relative strength after the next partner update.
• Use a tactical hedge: short IBB/XBI into any spike in biotech ETF inflows if 10-year real yields continue higher; biotech beta historically de-rates faster than defensives when discount rates rise.